Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING

Novel Candidate Protein Biomarkers Identified for Gastric Cancer

By Labmedica International staff writers
Posted on 25 Mar 2014
Image: Ultra nano-liquid chromatography system (Photo courtesy of Eksigent).
Image: Ultra nano-liquid chromatography system (Photo courtesy of Eksigent).
The early detection of stomach or gastric cancer (GC) has been revealed with the identification of four new biomarkers in the blood of human cancer patients.

This poor outcome of GC can be attributed to an extended asymptomatic period associated with this cancer, and difficulty in the detection of early stage gastric adenocarcinoma when treatment could improve long term survival of patients.

Scientists at the University of Adelaide (Australia) collected serum samples from 37 preoperative GC patients with intestinal type gastric adenocarcinoma. There were 10 females, with a mean age range of 69 ± 10 years and 17 males with a mean age range of 66 ± 11 years. In the cohort were 11 early stage cancer patients, and the controls included healthy and noncancerous patients with other gastric disease.

Enzyme-linked immunosorbent assays (ELISA) were performed for four proteins afamin, clusterin, haptoglobin and vitamin D binding protein (VDBP) and obtained from USCN Life Science Inc., (Wuhan, China). Ten GC and 10 controls serum samples were analyzed with multiple reaction monitoring high resolution mass spectrometry (MRM-HR). These serum samples were run on Triple TOF 5600 mass spectrometer (AB Sciex; Framingham, MA, USA) with an Ultra nano-liquid chromatography (LC) system (Eksigent; Redwood City, CA, USA).

The analysis of the ELISA results showed that the sensitivity and specificity values represented as Area Under the Curve (AUC) were: 0.94 for clusterin, 0.84 for VDBP, 0.58 for haptoglobin, and 0.52 for afamin. The MRM-HR data when analyzed revealed a trend for differential regulation of afamin, clusterin and VDBP. MRM-HR analysis revealed a significant higher abundance of haptoglobin in GC patients which was similar to that observed in the results from the ELISA. All four proteins were individually superior to a current clinical marker CA72-4 in discriminating stomach cancer from healthy controls.

The authors concluded that the differential regulation of four serum proteins in gastric cancer patients compared with normal healthy individuals were found with clusterin, VDBP and afamin down-regulated, and haptoglobin up-regulated in serum from GC versus benign GI disease cases. Peter Hoffmann, PhD, a professor at the University of Adelaide and senior author of the study said, “Stomach cancer is typically without symptoms in the early stages so most cancers are not diagnosed until the later stages, and the survival rates are therefore low. A noninvasive, inexpensive screening technique through a simple blood test for the early detection of stomach cancer would make a huge difference in the survival outcomes for people with this disease.” The study was published on February 7, 2014, in the journal Biochimica et Biophysica Acta.

Related Links:

University of Adelaide
AB Sciex
Eksigent



PURITAN MEDICAL
EUROIMMUN AG
Sekisui Diagnostics
comments powered by Disqus
Life Technologies

Channels

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Tech.

view channel
Image: The ADVIA Centaur XPT Immunoassay System delivers the results that clinicians depend upon for accurate diagnoses and better patient care (Photo courtesy of Siemens Healthcare).

Introduction of New Central Laboratory Clinical Analyzers Highlights Recent Lab Equipment Exposition

An impressive array of new automated analyzers for central diagnostic laboratories was unveiled at a recent lab equipment trade fair. The IFCC WorldLab exposition held June 22-26, 2014, in Istanbul... Read more

Industry News

view channel

EKF Wins Distribution Contract and Regulatory Approval for Target Regions

EKF Diagnostics Holdings (Cardiff, Wales, UK), an AIM-listed point-of-care, central laboratory and molecular diagnostics business, announced that it has signed a new distribution contract in China and that one of its OEM (original equipment manufacturer) partners has received further regulatory approval across several target... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.